Company Dossier · Health Care
Repligen
- Russell 1000
- MidCap 400
What Repligen is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $0.79 billion, up 18% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.11 billion, about level with a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.02 billion, about level with a year earlier.SEC EDGAR filings (XBRL)
- Latest earnings call or results release (July 28, 2026): sentiment 0.80 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.85 of 1.Palanor Discourse
- Guidance in the last 90 days: 6 outlook figures raised, 1 lowered, 2 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 26, 2026): 1 risk factor added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $5.0 million on the open market.SEC Form 4
- 481 institutional managers reported a position at June 30, 2026 (+36 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 1 (1 a year earlier).U.S. Department of Labor (OFLC)
Risk events (12 months): 1 — latest OSHA inspection, Mar 19, 2026 →
Company Posture
How Company Posture is measured →Company Posture covers S&P 500 companies.
Credit
How these are built →No bond term sheets or tagged debt on file for Repligen yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Repligen, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralA Look at Repligen Corp (RGEN) After 7.8% Decline -- GF Value $179.80 vs Price $177.23
gurufocus.com · via Marketaux · Oct 1, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 6, 20268-KAcquisition or sale completedItem 2.01
- Sep 29, 2026Patent
- Sep 15, 20268-KDirector or officer changeItem 5.02
- Sep 15, 2026Patent
- Sep 8, 2026Patent
- Jul 22, 20268-KMaterial agreement signedItem 1.01
- May 15, 20268-KShareholder vote resultsItem 5.07
- May 5, 2026Patent
- Apr 7, 2026Patent
- Mar 19, 2026Risk event
- Feb 26, 202610-KAnnual report (10-K)1 risk factors added, 0 removed
- Jan 6, 20268-KDirector or officer changeItem 5.02
- Nov 5, 2025Trademark
- Sep 2, 20258-KDirector or officer changeItem 5.02
- May 15, 20258-KShareholder vote resultsItem 5.07
- Mar 14, 202510-KAnnual report (10-K)3 risk factors added, 6 removed
- Feb 22, 202410-KAnnual report (10-K)3 risk factors added, 3 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Axsome Therapeutics AXSM | $0.8B | −$0.1B | Jun 30, 2026 |
| Arrowhead Pharmaceuticals ARWR | $0.7B | −$0.1B | Jun 30, 2026 |
| Caris Life Sciences CAI | $1.0B | $0.1B | Jun 30, 2026 |
| Insmed INSM | $1.1B | −$0.8B | Jun 30, 2026 |
| Halozyme HALO | $1.7B | $0.8B | Jun 30, 2026 |
| Moderna MRNA | $2.2B | −$1.2B | Jun 30, 2026 |
| Exelixis EXEL | $2.4B | $1.2B | Jul 3, 2026 |
| United Therapeutics UTHR | $3.1B | $1.1B | Jun 30, 2026 |